SARS-CoV-2 vaccine alleviates disease burden and severity in liver transplant recipients even with low antibody titers

We retrospectively assessed the clinical Pfizer’s mRNA SARS-CoV-2 BNT162b2 vaccination outcomes and the serologic impact on liver transplant (LT) recipients. PATIENTS AND METHODS: One hundred and sixty-seven LT cases followed between March 1, 2020 and September 25, 2021, and were stratified into two...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalaileh, Abed, Imam, Ashraf, Jammal, Alaa, Hakimian, David, Amer, Johnny, Shafrir, Asher, Milgrom, Yael, Massarwa, Muhammad, Hazou, Wadi, Khader, Majd, Safadi, Rifaat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894343/
https://www.ncbi.nlm.nih.gov/pubmed/36724131
http://dx.doi.org/10.1097/HC9.0000000000000025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894343/
https://www.ncbi.nlm.nih.gov/pubmed/36724131
http://dx.doi.org/10.1097/HC9.0000000000000025

Ejemplares similares